证券代码：300347 证券简称：泰格医药 公告编码（2024）054 号 杭州泰格医药科技股份有限公司 2024 年第三次临时股东大会决议的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 特别提示： 本次股东大会未出现否决议案的情形。 一、会议召开情况 1、会议召开时间 现场会议召开时间为：2024年10月8日（星期二）下午15：00 网络投票时间：2024年10月8日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为2024年10月8日上午9： 15—9：25，9：30—11：30和下午13：00—15：00；通过深圳证券交易所互联网投票系统进 行网络投票的具体时间为2024年10月8日上午9：15至2024年10月8日下午15：00的任意时间。 2、现场会议召开地点：杭州市滨江区聚工路19号盛大科技园A座18楼会议室 3、会议方式：本次股东大会采取现场投票和网络投票相结合的方式 4、召集人：杭州泰格医药科技股份有限公司董事会 5、现场会议主持人：公司董事长叶小平先生 6、本次股东大会会议的召集、召开与表决程序符合《公司法》、《上市 ...

杭州泰格医药科技股份有限公司 章程修订对照表 | 序号 | 原条款 | 修订后条款 | | --- | --- | --- | | | 第一条 为维护杭州泰格医药科技股份有 | | | | 限公司（以下简称"公司"）、股东和债 | | | | 权人的合法权益，规范公司的组织和行 | 第一条 为维护杭州泰格医药科技股份有 | | | 为，根据《中华人民共和国公司法》（以 | 限公司（以下简称"公司"）、股东和债 | | | 下简称《公司法》）、《中华人民共和国 | 权人的合法权益，规范公司的组织和行为， | | | 证券法》（以下简称《证券法》）、《国 | 根据《中华人民共和国公司法》（以下简 | | | 务院关于股份有限公司境外募集股份及上 | 称《公司法》）、《中华人民共和国证券 | | | 市的特别规定》（以下简称《特别规 | | | | 定》）、《到境外上市公司章程必备条 | 法》（以下简称《证券法》）、《境内企 | | | 款》（以下简称《必备条款》）、《关于 | 业境外发行证券和上市管理试行办法》 | | 1 | 到香港上市公司对公司章程作补充修改的 | （以下简称《境外上市管理办法》）、《国 | ...

证券代码：300347 证券简称：泰格医药 公告编码（2024）053 号 杭州泰格医药科技股份有限公司 关于对外投资暨关联交易公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述 或者重大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"或"泰格医药"）拟以现金方式受 让迪安诊断技术集团股份有限公司（以下简称"迪安诊断"）持有的上海观合医药科技 股份有限公司（以下简称"观合医药"）35.8322%股权、迪安诊断持有的诸暨观鹤企业 管理合伙企业（有限合伙）（以下简称"诸暨观鹤"）5.2200%财产份额、迪安诊断持有 的诸暨观荷三期企业管理合伙企业（有限合伙）（以下简称"诸暨观荷"）4.8883%财产 份额、迪安诊断持有的诸暨观合四期企业管理合伙企业（有限合伙）（以下简称"诸暨 观合"）2.5500%财产份额以及苏州瀛凯欣运企业管理咨询有限公司（以下简称"苏州瀛 凯"）持有的观合医药 3.6939%股权（以下简称"本次交易"）。本次交易完成后，公司 及全资子公司嘉兴欣格医药科技有限公司（以下简称"嘉兴欣格"）将合计直接及间接 持有观合医药72.8169%股权，观合 ...

经与会监事审议，本次会议以投票表决的方式审议通过如下决议： 证券代码：300347 证券简称：泰格医药 公告编码（2024）052 号 杭州泰格医药科技股份有限公司 第五届监事会第七次会议决议公告 公司及监事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）第五届监事会第七次会议于2024 年9月27日在杭州市滨江区聚工路19号盛大科技园A座18层会议室举行，本次会议以现场与 通讯表决相结合的方式召开。会议通知已于2024年9月25日以电话、电子邮件方式向全体监 事发出。会议应到监事3人，实到监事3人。本次会议由监事会主席张炳辉主持。本次会议 的召开及程序符合有关法律、法规和公司章程的要求，会议合法有效。 表决结果：同意3票；反对0票；弃权0票。 特此公告。 杭州泰格医药科技股份有限公司监事会 二〇二四年九月二十八日 2 一、审议并通过《关于对外投资暨关联交易的议案》。 公司拟以现金方式受让迪安诊断技术集团股份有限公司（以下简称"迪安诊断"）持有 的上海观合医药科技股份有限公司（以下简称"观合医药"）35.8322 ...

杭州泰格医药科技股份有限公司（以下简称"公司"）第五届董事会第十一次会议于2024 年9月27日在杭州市滨江区聚工路19号盛大科技园A座18层会议室举行，本次会议以现场与 通讯表决相结合的方式召开。会议通知已于2024年9月25日以电话、电子邮件方式向全体董 事发出。会议应到董事7人，实到董事7人，本次会议由公司董事长叶小平主持。本次会议 的召开及程序符合有关法律、法规和公司章程的要求，会议合法有效。 经与会董事审议，本次会议以投票表决的方式审议通过如下决议： 一、审议并通过《关于对外投资暨关联交易的议案》。 公司拟以现金方式受让迪安诊断技术集团股份有限公司（以下简称"迪安诊断"）持有 的上海观合医药科技股份有限公司（以下简称"观合医药"）35.8322%股权、迪安诊断持有 的诸暨观鹤企业管理合伙企业（有限合伙）5.2200%财产份额、迪安诊断持有的诸暨观荷三 期企业管理合伙企业（有限合伙）4.8883%财产份额、迪安诊断持有的诸暨观合四期企业管 理合伙企业（有限合伙）2.5500%财产份额以及苏州瀛凯欣运企业管理咨询有限公司（以下 简称"苏州瀛凯"）持有的观合医药3.6939%股权（以下简称"本次交易"）。 ...

证券代码：300347 证券简称：泰格医药 公告编码（2024）050 号 杭州泰格医药科技股份有限公司 关于持股5%以上股东新增质押的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）近日接到公司持股5%以上股东曹 晓春女士通知，获悉曹晓春女士办理其持有的部分股份被质押，具体内容如下： 二、累计质押情况 截至本公告出具日，上述股东及其一致行动人所持质押股份情况如下： | 股东 | 持股数量 | 持股 | 本次质押 | 本次质押 | 占其所 | 占公司 | 已质押股份 | 未质押股份 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | （股） | 比例 | 变动前质 | 变动后质 | 持股份 | 总股本 | 情况 | 情况 | 1 | | | | 押股份数 | 押股份数 | 比例 | 比例 | 已质押股份 | 占已质 | 未质押股份 | 占未质 | | --- | --- | --- | --- | --- | --- | ...

Financial Performance - For the six months ended June 30, 2024, the company's revenue was RMB 3,358.2 million, a decrease of 9.5% compared to RMB 3,710.9 million for the same period in 2023[8]. - Gross profit for the same period was RMB 1,333.0 million, down 10.0% from RMB 1,481.1 million year-on-year[8]. - Net profit attributable to the owners of the company was RMB 492.8 million, representing a significant decline of 64.5% from RMB 1,388.3 million in the previous year[8]. - The company's basic and diluted earnings per share were both RMB 0.57, a decrease of 64.6% compared to RMB 1.61 for the same period last year[8]. - The gross profit margin slightly decreased to 39.7% from 39.9% year-on-year[8]. - The net profit margin attributable to the owners of the company fell to 14.7% from 37.4% in the previous year, a decline of 22.7%[8]. - The adjusted net profit attributable to shareholders, excluding non-recurring items, was RMB 640.3 million, down 19.3% from RMB 793.5 million in the same period last year[8]. - The company did not declare any interim dividend for the six months ended June 30, 2024, consistent with the previous year[9]. Market and Strategic Focus - The company is focusing on enhancing its market presence and exploring new strategies for growth amid the declining financial performance[7]. - The board of directors has acknowledged the need for strategic adjustments to address the current market challenges and improve future performance[7]. - The company maintained a market share of 12.85% in the Chinese clinical outsourcing service market in 2023, ranking as the only Chinese contract research organization in the global top 10 with a market share of 1.46%[12]. - The company is focusing on early-stage investment opportunities in innovative biopharmaceutical and medical device startups to foster long-term partnerships and promote continuous innovation in the biopharmaceutical industry[82]. - The company aims to create a comprehensive lifecycle service platform for technology achievement transformation, integrating various resources for pharmaceutical innovation[82]. Clinical Trials and Research - In the first half of 2024, the number of new clinical trials initiated by the top 20 global pharmaceutical companies in China reached 293, accounting for 15.4% of global clinical trials, a significant increase from 9.8% in 2018[12]. - The number of ongoing drug clinical research projects increased from 772 as of June 30, 2023, and 752 as of December 31, 2023, to 800 as of June 30, 2024[12]. - The National Medical Products Administration approved 27 Class 1 innovative drugs in the first half of 2024, an increase of 4 compared to the same period in 2023[10]. - The number of clinical trials publicly announced by the China Center for Drug Evaluation reached 2,297 in the first half of 2024, an increase of 329 from the first half of 2023[10]. - The company provided services for 15 Class 1 innovative drugs approved in China in the first half of 2024 and assisted in the successful launch of 2 innovative medical device products[12]. Financial Assets and Investments - The total potential amount of overseas licensing transactions by Chinese biopharmaceutical companies reached $24.3 billion in the first half of 2024, representing a year-on-year growth of 110%[12]. - The company has committed additional capital of RMB 7 billion to invest in the joint venture Hangzhou Taikun as of June 30, 2024[69]. - The company's investment in non-listed equity increased by 6.6% to RMB 5,330.5 million from RMB 4,999.5 million, driven by continued investments in entities with growth potential and fair value gains of RMB 87.7 million[63]. - The investment in listed equity securities decreased by 58.4% to RMB 113.9 million from RMB 273.7 million, primarily due to a fair value loss of RMB 155.0 million during the reporting period[63]. - The company realized gains of RMB 69.3 million from exits in investments and funds, compared to RMB 152.3 million in the same period last year[63]. Employee and Operational Changes - The total number of employees decreased from 9,701 to 9,348, with a reduction in China due to strategic adjustments in response to industry cycles[15]. - The number of overseas employees increased from 1,632 to 1,722, reflecting the company's strategy to expand clinical operations and project management teams in key markets[17]. - The company established a Clinical Operations Strategy Committee to enhance clinical strategy capabilities and improve RFP success rates, leading to better order conversion[13]. - As of June 30, 2024, the US clinical operations team grew to nearly 100 employees, covering 42 cities across 21 states, with over 700 partnerships with clinical trial centers[13]. Risks and Compliance - The company faces risks from intensified competition in the global clinical contract research organization market, impacting pricing and profitability[93]. - Future business expansion and strategic implementation may face risks if not effectively managed, potentially affecting the company's financial performance[94]. - The company emphasizes the importance of compliance with current and future laws, regulations, and industry standards, as failure to do so could significantly impact its business, financial condition, and operational performance[95]. - The company requires multiple regulatory approvals, licenses, and certifications to operate, and failure to obtain or renew these could severely disrupt its business operations and financial performance[96]. - There is a risk of losing customers if they perceive that the services provided do not meet their expectations, which could adversely affect the company's revenue generation capabilities[97]. Shareholder and Governance - The company has approved a share repurchase plan with a total fund of no less than RMB 500 million and up to RMB 1 billion, with a maximum repurchase price of RMB 72.00 per share[160]. - The board approved the appointment of a new independent non-executive director on March 21, 2024, following the resignation of a previous director[163]. - As of June 30, 2024, Dr. Ye Xiaoping and Ms. Cao Xiaochun collectively hold 228,901,315 A shares, representing approximately 30.86% of the A shares and 26.46% of the total issued shares of the company[166]. - Major shareholders include 2017 Eagle Holdings LLC and F-J Sands Family I, LLC, each holding 14,606,581 H shares, which is 11.86% of the relevant class of shares and 1.69% of the total issued share capital[170]. - The company has adopted the principles and code provisions of the Corporate Governance Code and has complied with its provisions during the reporting period[173].

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Views - The company reported a revenue of 3.358 billion yuan for H1 2024, a year-on-year decrease of 9.50%, and a net profit attributable to shareholders of 493 million yuan, down 64.50% year-on-year [1] - In Q2 2024, the company achieved a revenue of 1.698 billion yuan, a year-on-year decline of 10.92%, but a quarter-on-quarter increase of 9.66% in net profit [1] - The company has shown stable growth in project numbers and has optimized its workforce, with a total of 9,348 employees as of H1 2024, down from 9,701 at the end of 2023 [1] - The clinical trial technology services segment saw a revenue of 1.637 billion yuan in H1 2024, a decline of 22.17% year-on-year, primarily due to a high base from specific vaccine projects in the previous year [1] - The company is actively investing in overseas markets, with a notable increase in orders from North America, where ongoing clinical trials have risen from 194 at the end of 2023 to 208 in H1 2024 [1] Financial Summary - For 2024, the company expects revenue growth to be flat, with a profit decline of 15%-20% [1] - Projected net profits for 2024-2026 are estimated at 1.643 billion yuan, 2.088 billion yuan, and 2.412 billion yuan, reflecting a year-on-year decline of 18.9% in 2024, followed by growth of 27.1% in 2025 and 15.5% in 2026 [1][2] - The company's P/E ratios for 2024, 2025, and 2026 are projected to be 26X, 21X, and 18X respectively [1]

证券代码：300347 证券简称：泰格医药 公告编码（2024）049 号 杭州泰格医药科技股份有限公司 关于召开 2024 年第三次临时股东大会的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 一、召开会议的基本情况 1．股东大会届次：2024年第三次临时股东大会。 2．股东大会的召集人：公司董事会。 3．会议召开的合法、合规性：经公司第五届董事会第十次会议审议通过，决定召开 2024年第三次临时股东大会，召集程序符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 4．会议召开的日期、时间： 现场会议召开日期和时间：2024 年10 月8 日（星期二）下午15:00 点 网络投票日期和时间： 1 席现场会议； （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统 （http://wltp.cninfo.com.cn）向全体股东提供网络投票平台，股东可以在本公告公布的网络 投票时间内通过上述系统行使表决权； （3）同一表决权只能选择现场投票、深圳证券交易所交易系统投票、深圳证券交易所 互联网投票系统投票中的一种方式，不 ...

呈交日期: 2024年9月4日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 741,823,770 | RMB | | 1 RMB | | 741,823,770 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 741,823,770 | RMB | | 1 RMB | | 741,823,770 | 本月底法定/註冊股本總額： RMB ...